6.110 0.00 (0.00%)
After hours: 4:02PM EST
|Bid||6.070 x 900|
|Ask||6.080 x 4000|
|Day's Range||5.94 - 6.12|
|52 Week Range||4.23 - 7.79|
|Beta (3Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.63|
Fitbit is following a stellar 2018, which saw it bounce back to profit thanks in part to its Versa smartwatch, by diving even further into healthcare. As part of a new team-up with the National Institutes of Health (NIH), Fitbit is letting users sync their accounts with the All of Us research program: a US-wide initiative that wants to use data based on "individual differences in lifestyle, environment, and biology" to help treat and prevent diseases. Announced in 2015, the program aims to include insights from at least one million participants to help deliver precision medicine.
One of Apple's (NASDAQ:AAPL) bright spots for 2018 was the Apple Watch. The smartwatch continues to lead the industry in sales, and saw significant growth in 2018. With the release of the Series 4 in September, AAPL introduced advanced health features, and that move is showing signs of paying off in a big way. The company is reportedly in talks with private Medicare plans about subsidizing the Apple Watch for seniors. 2019 may be starting off on a rough note when it comes to iPhone sales, but as it approaches its fourth birthday, the Apple Watch is poised to contribute a bigger share to AAPL revenue -- without depending on consumers to open their wallets. ### Report: AAPL in Talks With Private Medicare Plans CNBC reports that Apple is in talks with at least three private Medicare plans about providing a subsidized Apple Watch to members over age 65. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Top 10 Global Stock Ideas for 2019 From RBC Capital Introduced last September, the Apple Watch Series 4 (read our review here) incorporates advanced new health features, including a built-in ECG test and fall detection. The Apple Watch competes with smartwatches like those from Fitbit (NYSE:FIT), which offer health features like heart rate tracking, but lack the capabilities AAPL introduced in the fall. According to CNBC, there are currently about 19 million seniors enrolled in a Medicare Advantage plan. That's notable because this tier of plans receives government payouts averaging $10,000 per member, giving more flexibility for the plan providers to invest in new preventative technology. AAPL is making the case for some of that cash to go toward purchasing an Apple Watch. ### Spending Money to Save Money How would the economics of giving an Apple Watch to a member work in favor of the insurers? After all, an Apple Watch Series 4 starts at $399. The 2017 Series 3 -- which still has many health features but lacks ECG and fall detection- goes for $279 and up. That is a significant investment. CNBC quoted the CEO of Medicare Advantage plan provider Bright Health, who said, "Avoiding one emergency room visit would more than pay for the device." In addition, if AAPL can show that the Apple Watch could help Medicare members detect potentially serious health problems before they reach the stage where a costly medical intervention is required, insurers would count that as a big win. According to data from the National Bureau of Economic Research, the average cost to health insurers for the first 90 days after a heart attack is $38,501. In addition, Medicare pays an additional $14,000 per patient in hospital bills the year following a heart attack, with more costs for outpatient treatment and physicians. That's well over $52,000 in one year. In comparison, $279 or $399 for an Apple Watch that could help to detect an underlying heart condition for treatment that prevents a heart attack suddenly seems like a bargain… ### Apple Watch Could Be Poised for Big Growth When the Apple Watch first launched in 2015, it failed to meet lofty sales expectations. The device dominated the fledgling smartwatch market, but lacked mass market appeal. AAPL quickly pivoted and began to reposition its smartwatch for the fitness crowd with positive results. In 2018, the company continued to push fitness capabilities, but added a focus on health to the mix with the Apple Watch Series 4. In Q3 2018, AAPL saw 54% growth in sales for its smartwatch. Apple has already been successful in convincing other health industry companies to provide subsidized Apple Watches. For example, CNBC points to a 2017 deal with life insurance company John Hancock that provided an Apple Watch for $25 to members of its Vitality plan who committed to exercising regularly for two years. * 7 Stocks to Buy as the Dollar Weakens At a time when the company -- and Apple stock -- is feeling the effect of declining demand for its bread and butter iPhone, the Apple Watch has potential. And if AAPL is successful in tapping the health market, Apple Watch sales could explode far beyond consumer levels. As of this writing, Brad Moon did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Growth Stocks With the Future Written All Over Them * 7 Reasons Why Buffett's Bet on Apple Stock Is a Good One * 10 Companies That Could Post Decelerating Profits Compare Brokers The post Apple Talking to Medicare About Apple Watch for Seniors appeared first on InvestorPlace.
With the advent of artificial intelligence, big data, vehicle automation, and a plethora of other futuristic developments coming out of the space, it makes sense that investors are interested in the development of companies from the multi-billion dollar industry, and as a result of the recent increase of favorable public opinions, the tech industry may see gains as a result of this industry gaining favorable market opinion. XSport Global, Inc. (XSPT), Ability Inc (ABIL), STMicroelectronics NV (STM), and Fitbit Inc (FIT) are 4 tech stocks representing companies innovating towards the future. In late-November 2018, XSport Global, Inc. (XSPT) announced their rapid development of FitLinkDNA, a service designed to help athletes train, compete, and perform at their full capacity.
Fitbit (FIT), the leading global wearables brand, and the National Institutes of Health (NIH) today launched the Fitbit Bring-Your-Own-Device (BYOD) project, the first digital health technology initiative for the All of Us Research Program. Fitbit users currently enrolled in the program can now choose to sync their Fitbit accounts to help researchers unlock deeper insights into the relationships between health indicators such as physical activity, heart rate, sleep and health outcomes. Participants will be invited to share different types of health information over time through surveys, electronic health records, physical measurements, biosamples and digital health technologies.
Alphabet Updates: Lawsuits, EU Expansion, Malta, and Verily(Continued from Prior Part)Verily raises funds for acquisitionsAlphabet’s (GOOGL) Verily subsidiary recently raised $1.0 billion in additional capital from a group of investors led by
Shares of the fitness bracelet and smartwatch maker are beating the market so far this year, but staying in the black after three years of double-digit declines won't be easy.
# Fitbit Inc ### NYSE:FIT View full report here! ## Summary * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is moderate for FIT with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 2. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $4.72 billion over the last one-month into ETFs that hold FIT are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
On May 9th, 2018, another user submitted a new topic for discussion, titled, "Add pregnancy for more accurate cycle prediction in Female Health Tracking." It's still active and its status is currently, "Reviewed by moderator." In the thread, community managers respond to some users, calling their suggestions for pregnancy features "interesting" and "useful." The most recent moderator response is from December 17th, and it reads, "Hopefully we will have support from other users since more votes and comments an idea has the more visibility and momentum it gains." The thread has 180 comments and 1,014 upvotes (and counting). There are numeroussimilar threads on MyFitnessPal forums, also dating back to 2013. The most lauded option is the Withings Pregnancy Tracker in the Health Mate app, which ideally connects to a Nokia smart scale and can use imported data from MyFitnessPal.
Fitbit (NYSE:FIT) is the type of stock investors can talk themselves into. FIT stock can look cheap, trading at about 0.4 times its revenue, after backing out its net cash. Its cash, based on its fourth-quarter free cash flow guidance, by the end of 2018 should have reached roughly half the market capitalization of Fitbit stock. As a result, FIT stock, at worst, will have a lot of time to turn itself around. But I've long been skeptical toward Fitbit stock, and truthfully not all that much has changed. Aspects of Fitbit's balance sheet and valuation are intriguing. FIT as a business, however, hardly looks attractive. Its 2018 guidance suggest that its sales ended up declining last year. And its adjusted EBITDA was negative, even after excluding its nearly $100 million of share-based compensation. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Morgan Stanley: 7 Risky Stocks to Sell Now But FIT can improve. Back in October, I even called out Fitbit as one of 16 potential turnarounds. But it will have to improve a great deal before its results can support the current price of Fitbit stock. And FIT still hasn't shown nearly enough strength to cause investors to expect that improvement. ### The Optimism Toward Fitbit Stock There's been some optimism toward FIT of late. Fitbit stock has risen 34% just since late October. A Q3 earnings beat certainly helped its cause. And as Larry Ramer pointed out a week later, it seemed like Fitbit was headed in the right direction while Apple (NASDAQ:AAPL) went the wrong way, a noted reversal from recent trends. That said, this seems more like a "dead-cat bounce" for FIT stock than a real rally. The 34% gains have come off an all-time low for Fitbit stock. The shares are still down about 4% over the past year. FIT essentially hasn't moved since the beginning of 2017, even as the broad markets in general and tech in particular have done quite well. And FIT still remains a long, long way from supporting the current price of Fitbit stock. ### The Financial Problem Facing FIT Stock Fitbit's obvious problem is that its business is declining. Its 2018 top-line guidance of about $1.5 billion is almost 20% below its 2015 revenue. Moreover, its 2018 gross margin should be down 700 basis points or so versus 2017 because Fitbit has lost its pricing edge amid competition from Apple and Garmin (NASDAQ:GRMN). FIT is still unprofitable in terms of both operating income and EBITDA. Its cost cuts lowered its operating expenses by about 7% in both 2017 and 2018, assuming it meets its 2018 cost-cutting guidance. There shouldn't be much more room left for additional cost savings, and Fitbit has to spend money to compete against its larger rivals. To reiterate a point I've made before, it's worth considering what would be required for FIT stock to have a still-rather-aggressive price-earnings multiple of 30. At the current price of FIT stock, in order to reach that multiple, FIT would require 19c of adjusted earnings per share. With 267 million shares and a 25% tax rate (both reflect the company's guidance), FIT needs $68 million in pre-tax profit. But its 2018 operating loss was likely at least $100 million, even excluding another $100 million of share-based compensation. So Fitbit has to add $168 million of profit - or 11% of its revenue - just for FIT stock to reach a P/E multiple of 30. How, exactly, can it generate an additional $168 million of profit? Its operating expenses probably can't drop much more. Its gross margin continues to decline, and pricing pressure will probably place a ceiling on that as well. If that's the case, with a gross margin of 40%+, the company would have to increase its sales by about $420 million, or nearly 30%, with no associated increase in its sales, general and administrative costs. Realistically, Fitbit needs its revenue to grow roughly 50%, given that its operating expenses have to start rising at least somewhat along with its revenue. And, in this model, that revenue growth would only support the current price of Fitbit stock. ### The Bet on Fitbit Stock That revenue growth seems unlikely to materialize. Fitbit is hoping to benefit from partnerships with insurers and corporations to drive demand for its products. But that demand can go to Garmin, Apple, and Samsung as well. And there seems little reason at this point to trust Fitbit to execute well. So really the only bullish thesis for Fitbit stock that makes any sense is the belief that it can be acquired. It seems highly unlikely that Fitbit can grow enough on its own to support the current valuation of Fitbit stock. But could FIT be acquired? Perhaps. But that, too, seems like a risky bet. Alphabet (NASDAQ:GOOGL,GOOG) could be a potential, logical acquirer, given its hardware aspirations. But it's not as if Alphabet can cut Fitbit's roughly $740 million of operating expenses by $100 million. Alphabet would still have to buy an unprofitable business that needs a turnaround. Other companies potentially could be interested at some point, but FIT almost certainly has to show revenue growth and improve its margins first. And so we circle back to the company's key problem. FIT simply doesn't have a very good business. Its sales are declining, and its competition is intense, while its execution has been subpar. And we've already seen the "commoditization" thesis play out with smartphones and upend Apple stock. The same "race to the bottom" pricing will hit wearables and smartwatches over time. Despite all that, FIT stock, by any metric other than price-revenue, is sharply overvalued. That's a tough combination and one that needs to change. Truthfully, after three years of disappointing results by FIT, I see little reason to believe it will. As of this writing, Vince Martin has no positions in any securities mentioned. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Why You Shouldn't Bet on Fitbit Stock appeared first on InvestorPlace.
I have spoken a lot about analysts' favorite stocks to buy. But along with buying comes the stocks to sell. You have to know when to cash out at the right time. This is all the more important given the current market conditions. Even top-rated stocks are getting hammered right lately. Luckily Morgan Stanley is out with its list of the stocks you should sell now. These stocks all have a "sell" rating from the firm and "an unfavorable risk-reward skew." As the firm explains, these companies are "facing challenges that are independent of cyclical trends." The worst part is that they could even lose over half their value in the next 12-18 months. These challenges include everything from market-share loss and rising competition to deteriorating end markets and cost pressures. In short, when it comes to these stocks, save your money. There are much more worthy investing opportunities out there. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks You Can Set and Forget (Even In This Market) Here I also use TipRanks market data to get a better idea of where these stocks are heading. What's the rest of the Street saying, for example? Let's take a closer look these even stocks to sell: ### Juniper Networks (JNPR) Click to Enlarge Morgan Stanley says "sell" networking and cybersecurity stock Juniper Networks (NYSE:JNPR). The firm isn't alone in its bearish take on this stock. Goldman Sachs' Rod Hall (Track Record & Ratings) is also advising investors to spend their money elsewhere -- and put this on their list of stocks to sell when the price is right. The analyst stated "we would advise investors to use any strength to reduce exposure as we believe 2019 forecasts remain overly optimistic for Routing just on the basis of deflation in the data center." Hall continued: "Beyond this we believe that 2019 is a year of routing architecture transition in U.S. carrier networks toward lower cost ports and software as Verizon's 5G build gains some momentum as does the fully automated network solution that we believe comes along with 5G." Indeed, long-term concerns -- and a lack of catalysts -- keep Rosenblatt's Ryan Koontz in the bear camp. "We expect continued pricing and top line pressure to drive gross margin weakness and earnings below consensus over 4Q18 through FY19" he writes. Both Hall and Koontz believe the stock looks overvalued at current levels. Hall is modelling for a potential 25% drop in shares; Koontz for 10%. That's with shares already down 2% on a three-month basis. Not that JNPR doesn't have its supporters. Four analysts still rate the stock a "buy." Hence its "hold" Street consensus. Interested in JNPR? Get a free JNPR Stock Research Report. ### Hertz Rental (HTZ) Click to Enlarge Leave while you can! Morgan Stanley's Adam Jonas (Track Record & Ratings) has just reiterated a "sell" rating on Hertz Global Holdings (NYSE:HTZ). Although high prices in used vehicles "saved" third-quarter results, he is troubled by a dangerous trio of rising finance costs, secular pressures and weakness in rental car pricing. According to the firm, the rental-car company is highly exposed to the peaking used car and auto credit markets. "We continue to believe HTZ confronts substantial secular problems in car rental manifesting in slower growth and cost headwinds for depreciation and cost of funds," writes Jonas. "We would use the recent stabilization of the stock price as an opportunity to reduce exposure." * The 7 Best Stocks in the Entrepreneur Index He has a $15 price target on the stock (7% upside from current levels). Bear in mind, shares have already plunged 35% year-to-date. And as we can see above, the company holds a fairly damning "moderate sell" Street consensus, making this a smart stock to sell. Get the HTZ Stock Research Report. ### Abercrombie (ANF) Click to Enlarge It's best to put struggling fashion retailer Abercrombie & Fitch (NYSE:ANF) on your stocks to sell list for now. That's the advice not just of Morgan Stanley, but the Street in general. This is a stock with a "moderate sell" Street consensus, and an average price target that suggests shares could fall 12%. However, Morgan Stanley's price target of just $14 suggests a much deeper pullback of 34% is possible. ANF is in the midst of a major organizational, product and strategy overhaul in an effort to stabilize its top-line efforts which are accelerating share gains out of Hollister (58% of 2017 sales) and slowly taking root in the A&F brand (42% of sales). "These updates could not be more necessary, in our view, with the company ending 2016 with productivity and profitability at trough levels, including a (0.3%) EBIT margin" writes RBC Capital's Brian Tunick (Track Record & Ratings). Another worrying thought -- with 25% short interest, expect shares to remain volatile. Right now, the stock is trading down 18% in the last six months, but has gained 7% over the last three months. Get the ANF Stock Research Report. ### Bed Bath & Beyond (BBBY) Click to Enlarge The situation for home-retail store Bed Bath & Beyond (NASDAQ:BBBY) is looking increasingly perilous. * Shares have crashed 44% in the last one year. * The Street consensus is "moderate sell," with analysts tilting towards sell over hold. * Even after such dramatic losses, the average analyst price target of $10.50 still indicates shares will fall rather than rise (the current share price is $12.06). So we are looking at downside of 14% right now. * Citi has just lowered its PT from $13 to $10, while Wolfe Research's PT has also shrunk from $15 to $10 * And on top of all that, Argus analyst Chris Graja (Track Record & Ratings) downgraded Bed Bath & Beyond to Hold from Buy. He cites a lack of confidence in the company meeting long-term targets, ongoing gross margin pressure, declines in store traffic and overspending. Let's close this stock with the words of Wells Fargo's Zachary Fadem: "With the benefits of Toys 'R Us closures, a strong consumer environment and a host of ambitious company initiatives failing to materialize in our view thus far, we remain bearish … and see further downside risk ahead." * 9 A-Rated Safety Stocks for a Grossly Oversold Market Add in the threat of e-commerce giant Amazon (NASDAQ:AMZN), and you can see why it's best to put this is the "stocks to sell" pile. Get the BBBY Stock Research Report. ### Fitbit (FIT) Click to Enlarge Even a recent earnings beat was not enough to convince the Street that Fitbit Inc (NYSE:FIT) is a worthy investing proposition. The fitness tracker maker has had a hard time on the market since it went public in 2015. And it doesn't look like a turnaround is coming any time soon. In fact, in the last five years, share prices have almost halved. Now Morgan Stanley says this is a "sell" rating stock, with a price target of just $4. From current levels that means we are looking at downside potential of over 25%. The firm's Yuuji Anderson (Track Record & Ratings) remains skeptical that the improvements with Charge 3 and Versa can make up for ongoing legacy declines. Fitbit Charge 3 is a heart rate fitness tracker that tracks activity, exercise and sleep, while the Versa is FIT's $199 smartwatch, and answer to the Apple Watch. Anderson thinks the current pace of new features is not enough to stabilize declining demand this year and expects shares to underperform into 2019. Most damning is the feedback from Citi analyst Jim Suva. He maintains a "sell" rating on the stock with a $5 price target. The problem: even though they may be cheaper, Fitbit's new products "are not as smart as the Apple watch". Overall, the Street consensus on FIT stands at a slightly more positive "hold." Get the FIT Stock Research Report. ### Macy's (M) Click to Enlarge Hot on the heels of Morgan Stanley's Sell rating for Macy's (NYSE:M) comes another bearish turn. This time it's from Atlantic Equities analyst Daniela Nedialkova (Track Record & Ratings). She has just downgraded M from "hold" to "sell." That's with a $28 price target, exactly in line with Morgan Stanley. From current levels that means both firms see prices dropping 5%. Nedialkova puts her move down to unrealistic market expectations. She comments "With prior year comparisons turning tougher for the next several quarters, we see expectations as too high. Macy's is continuing to execute on its strategic initiatives but we do not expect to see a material impact in the numbers until later in the year." For example, the company is currently investing $200 million in its Growth50 initiative. This is an experimental retail strategy offering expanded curated merchandise to 50 key locations. * 10 Oversold Stocks Due for a Bounce However these rewards will take time to materialize, and in the meantime expect trading to stay choppy: "As we expect most of 2019 will still be a year of transition, and with upcoming difficult prior year comparisons, we expect more volatility from the stock and given currently high expectations, see downside risk." Get the M Stock Research Report. ### United Natural Foods (UNFI) Click to Enlarge United Natural Foods (NYSE:UNFI) is a distributor of natural and organic and specialty foods across the U.S. and Canada. Its also the primary distributor to Amazon's Whole Foods Market. However, this isn't enough to save the stock from a pretty poor stock rating. Not one top-performing analyst rates the stock a "buy," and the overall consensus is "hold." A lot of people put this on their stocks to sell list already. That's with shares losing a disastrous 75% of their value in the last year. As you can imagine, analysts are not recommending a buy-the-dip type scenario here. For example, Morgan Stanley's Vincent Sinisi (Track Record & Ratings) has a "sell" rating on UNFI. He made the call following the news that UNFI would buy supermarket chain SuperValu. The deal was valued at a cool $2.9 billion. While "notable potential growth opportunities exist" for the combined company, integration risks leave Sinisi concerned. First quarter results provided fresh disappointment -- and caution. SuperValu reported a very soft first half of the year, with wholesale EBITDA declining more than 20% to $131M from $165M in the prior year. "With a bottom less clear in UNFI shares and limited margin for error given very high leverage levels, we believe investors should tread cautiously from here" sums up Oppenheimer's Rupesh Parikh. "Execution at SVU remains the key risk, especially against the current difficult grocery backdrop" he concludes. Get the UNFI Stock Research Report. TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy for Winning the Online Battle * The 7 Best Stocks in the Entrepreneur Index * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Morgan Stanley: 7 Risky Stocks to Sell Now appeared first on InvestorPlace.
Apple (NASDAQ:AAPL) stock has been hit hard by a slowdown in iPhone sales. This makes some sense, as the Apple iPhone represents nearly 60% of Apple revenue. This has also made AAPL stock super cheap: You were paying just 2.6 times sales to own Apple on Jan. 8, and 12.4 times earnings. That's not even counting the cash hoard, estimated at $237 billion in November. The reason for the market's fear is that investors don't see a new catalyst for Apple's growth. If smartphones are a commodity, and China can make a high-end phone its consumers love for less, where is the growth going to come from? InvestorPlace - Stock Market News, Stock Advice & Trading Tips The answer for AAPL stock is medicine. ### Apple Stock and the Medical Market While analysts are squirreled away in San Francisco's Westin St. Francis Hotel, watching the JPMorgan Chase (NYSE:JPM) Healthcare Conference, oohing and aahing over the latest drugs, Apple is quietly turning its Watch into a next-generation medical device. * 7 High-Risk Chinese ETFs to Avoid ... For Now Chronic conditions like diabetes, arthritis and heart disease were a $1.1 trillion market, just in the U.S., just in 2016. Those numbers are rising as people age worldwide. Much of that money is wasted on people forgetting to take their medicines or monitor things like blood pressure and blood sugar levels. AAPL wants to change that through Food and Drug Administration (FDA) approval of medical features on the Watch, like a heart monitor and a system for detecting falls. That Life Alert bracelet your grandma uses can cost up to $90 per month to monitor. The Apple Watch 4 costs $400. Which do you think she would prefer this Mother's Day? The big breakthrough for the Watch would be in diabetes care. A third-party product, OneDrop, now integrates its glucose monitoring platform with the Apple Watch. The benefits are not theoretical. Jason Perlow, a former colleague of mine at ZDNet, wrote in September that the Apple Watch saved his life. Early detection probably prevented a stroke. A Florida teen learned of a chronic kidney condition from the Watch's heart beat detection function. ### A Medical Ecosystem In 2019, anecdotes are going to become data, and pressure is going to grow for people who have chronic conditions, or might have them, to monitor themselves more closely. Eventually this pressure is going to come from the medical community. Apple rivals from Alphabet (NASDAQ:GOOGL) to Fitbit (NYSE:FIT) are working toward making their wearables into medical devices, but Apple is years ahead, at least in terms of getting approval from federal regulators. Apple doesn't yet break out the Watch in its financials. It's part of the company's "other products" group, which includes Apple TV, the Beats headphones and other products. But sales within that group were up 31% year-over-year in the third quarter and came to 6% of revenue. * 7 5G Stocks to Buy as the Race for Spectrum Tightens The Apple Watch became the dominant fitness band in the U.S. market during 2018, with IDC estimating 4.2 million were shipped in the September quarter alone, up from 2.7 million a year earlier. ### The Bottom Line on AAPL Stock Compared with the iPhone, the Apple Watch is still a niche product. But Apple Watch sales are growing, they are due to explode, and this will add enormously to the Apple ecosystem, maintaining and possibly even expanding the iPhone market share. Services tied to the AppleWatch should also start contributing to earnings as we enter the 2020s. Right now, you can buy all this potential for practically nothing. So long as Apple stock remains down over the high-end iPhone, at under 15 times earnings, you're getting the Watch business free. For an investor with a three to five-year time horizon, bargains like this should be irresistible. Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at firstname.lastname@example.org or follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in AAPL. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy for Winning the Online Battle * The 7 Best Stocks in the Entrepreneur Index * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post The Future for Apple Stock Is Medicine, Not the iPhone appeared first on InvestorPlace.
# Fitbit Inc ### NYSE:FIT View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is moderate for FIT with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 2. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding FIT is favorable, with net inflows of $11.37 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.